The disposition of intravenous doxapram in man

John A Clements, R H Robson, L F Prescott

Research output: Contribution to journalArticle

Abstract

The pharmacokinetics of intravenous doxapram in healthy individuals is consistent with a 3-compartment open model. Doxapram was administered by bolus injection (1.5 mg/kg-1) and by intravenous infusion (6.5 mg/kg-1 for 2 h) to 5 subjects on separate occasions. There was no significant difference in mean terminal plasma half-lives (355 and 448 min) or in mean total body clearances (5.9 and 5.6 ml/min-1/kg-1) following i.v. bolus injection or infusion respectively. In 3 subjects plasma doxapram concentrations during and after i.v. infusion agreed with those predicted from pharmacokinetic values obtained from the bolus injection study. Since mean steady-state concentrations (9.9 µg/ml-1) would be reached only after an extended interval (mean 15.2 h), a variable-rate infusion regimen was calculated to produce and maintain a concentration of 2 µg/ml-1 from 15-25 min onwards. A regimen in which the infusion rate is reduced step-wise is recommended to achieve early near-constant plasma doxapram concentrations.

Original languageEnglish
Pages (from-to)411-416
Number of pages6
JournalEuropean Journal of Clinical Pharmacology
Volume16
Issue number6
Publication statusPublished - 1979

Fingerprint

Doxapram
Injections
Pharmacokinetics
Intravenous Infusions

Cite this

Clements, J. A., Robson, R. H., & Prescott, L. F. (1979). The disposition of intravenous doxapram in man. European Journal of Clinical Pharmacology, 16(6), 411-416.
Clements, John A ; Robson, R H ; Prescott, L F. / The disposition of intravenous doxapram in man. In: European Journal of Clinical Pharmacology. 1979 ; Vol. 16, No. 6. pp. 411-416.
@article{658358687b984384bc15734c1b527860,
title = "The disposition of intravenous doxapram in man",
abstract = "The pharmacokinetics of intravenous doxapram in healthy individuals is consistent with a 3-compartment open model. Doxapram was administered by bolus injection (1.5 mg/kg-1) and by intravenous infusion (6.5 mg/kg-1 for 2 h) to 5 subjects on separate occasions. There was no significant difference in mean terminal plasma half-lives (355 and 448 min) or in mean total body clearances (5.9 and 5.6 ml/min-1/kg-1) following i.v. bolus injection or infusion respectively. In 3 subjects plasma doxapram concentrations during and after i.v. infusion agreed with those predicted from pharmacokinetic values obtained from the bolus injection study. Since mean steady-state concentrations (9.9 µg/ml-1) would be reached only after an extended interval (mean 15.2 h), a variable-rate infusion regimen was calculated to produce and maintain a concentration of 2 µg/ml-1 from 15-25 min onwards. A regimen in which the infusion rate is reduced step-wise is recommended to achieve early near-constant plasma doxapram concentrations.",
author = "Clements, {John A} and Robson, {R H} and Prescott, {L F}",
year = "1979",
language = "English",
volume = "16",
pages = "411--416",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer",
number = "6",

}

Clements, JA, Robson, RH & Prescott, LF 1979, 'The disposition of intravenous doxapram in man', European Journal of Clinical Pharmacology, vol. 16, no. 6, pp. 411-416.

The disposition of intravenous doxapram in man. / Clements, John A; Robson, R H; Prescott, L F.

In: European Journal of Clinical Pharmacology, Vol. 16, No. 6, 1979, p. 411-416.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The disposition of intravenous doxapram in man

AU - Clements, John A

AU - Robson, R H

AU - Prescott, L F

PY - 1979

Y1 - 1979

N2 - The pharmacokinetics of intravenous doxapram in healthy individuals is consistent with a 3-compartment open model. Doxapram was administered by bolus injection (1.5 mg/kg-1) and by intravenous infusion (6.5 mg/kg-1 for 2 h) to 5 subjects on separate occasions. There was no significant difference in mean terminal plasma half-lives (355 and 448 min) or in mean total body clearances (5.9 and 5.6 ml/min-1/kg-1) following i.v. bolus injection or infusion respectively. In 3 subjects plasma doxapram concentrations during and after i.v. infusion agreed with those predicted from pharmacokinetic values obtained from the bolus injection study. Since mean steady-state concentrations (9.9 µg/ml-1) would be reached only after an extended interval (mean 15.2 h), a variable-rate infusion regimen was calculated to produce and maintain a concentration of 2 µg/ml-1 from 15-25 min onwards. A regimen in which the infusion rate is reduced step-wise is recommended to achieve early near-constant plasma doxapram concentrations.

AB - The pharmacokinetics of intravenous doxapram in healthy individuals is consistent with a 3-compartment open model. Doxapram was administered by bolus injection (1.5 mg/kg-1) and by intravenous infusion (6.5 mg/kg-1 for 2 h) to 5 subjects on separate occasions. There was no significant difference in mean terminal plasma half-lives (355 and 448 min) or in mean total body clearances (5.9 and 5.6 ml/min-1/kg-1) following i.v. bolus injection or infusion respectively. In 3 subjects plasma doxapram concentrations during and after i.v. infusion agreed with those predicted from pharmacokinetic values obtained from the bolus injection study. Since mean steady-state concentrations (9.9 µg/ml-1) would be reached only after an extended interval (mean 15.2 h), a variable-rate infusion regimen was calculated to produce and maintain a concentration of 2 µg/ml-1 from 15-25 min onwards. A regimen in which the infusion rate is reduced step-wise is recommended to achieve early near-constant plasma doxapram concentrations.

UR - http://www.scopus.com/inward/record.url?scp=0018644012&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 411

EP - 416

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 6

ER -

Clements JA, Robson RH, Prescott LF. The disposition of intravenous doxapram in man. European Journal of Clinical Pharmacology. 1979;16(6):411-416.